PURPOSE OF THE STUDY
A better understanding on how
hypoglycaemia (hypos) affects people
living with insulin treated diabetes.
WHO CAN APPLY FOR THE STUDY?
People with type 1 diabetes or type 2
diabetes using insulin who experienced
any symptoms of hypoglycaemia in the last
HOW LONG WILL IT LAST?
The study devices are used for a 10 week
period and a follow up visit is done in 1 year.
Contact: firstname.lastname@example.org or +44 7398356909
Study sponsored and conducted by: King's College London, as part of Hypo-RESOLVE: www.hypo-resolve.eu
Hypo-RESOLVE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460.
The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA, T1D Exchange, JDRF,
International Diabetes Federation (IDF), The Leona M. and Harry B. Helmsley Charitable Trust.
WHAT DO I GET FOR TAKING PART?
Glucose data at the end of the 10 week period
Free Fitbit charge 4
£100 voucher when completing the study
WHAT WILL HAPPEN IF I TAKE PART?
After consent we will provide you with a:
FreeStyle Libre 2 ('blinded' - readings
are not visible to you);
Fitbit charge 4 activity monitor (records
sleep and activity pattern);
We ask you to answer questions through
the app about any hypoglycaemia you may
have experienced while using the Fitbit and
FreeStyle Libre 2.
lowered, allowing many products to
receive emergency approvals and
advance their commercialization
and deployment faster than they
would normally have been able
to. This then extended to larger
companies with more ambitious
aims around general remote patient
monitoring and management using
digital systems, which have been in
development for some time but saw
more launches and announcements
as progress accelerated.
The report makes it clear that
electronic skin patches as a product
category is extremely diverse. There
are different drivers, regulatory
situations, and underlying trends
in many of the different markets
where skin patches are relevant.
Each product sector has a drastically
different set of drivers, competitive
landscape and outlook, and skin
patch-based options fit within each
in a very unique way.
Another report by MEDTECHDIVE
says, 'CGM and insulin pump players
look to 2021 as watershed year for
diabetes wearables market with the
recent skyrocketing of virtual care
due to the coronavirus pandemic.
Patients embraced devices like
continuous glucose monitors and
insulin pumps in recent years before
the pandemic, and companies in
these markets like Dexcom and
Insulet or Medtronic and Abbott
Laboratories have remained
successful despite the economic
volatility throughout 2020." To read
the full report, CLICK HERE.
*Since 1999 IDTechEx has
provided independent market
research, business intelligence and
events on emerging technology to
clients in over 80 countries and
who use its insights to help make
strategic business decisions and
grow their organizations. IDTechEx is
headquartered in Cambridge, UK with
subsidiaries in Japan, Germany and